Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3 - Lee, Jung-Yun; Lee, Yoo-Young; Park, Jeong-Yeol; Shim, Seung-Hyuk; Kim, Se Ik; Kong, Tae-Wook; Lim, Chul Kwon; Cho, Hyun Woong; Suh, Dong Hoon (Journal of gynecologic oncology, 2023)
Keywords: Antineoplastic Agents - therapeutic use; Female; Genital Neoplasms, Female - drug therapy; Humans; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Poly(ADP-ribose) Polymerase Inhibitors - adverse effects; Review; Uterine Cervical Neoplasms - drug therapy; 산부인과학; Hyperthermic Intraperitoneal Chemotherapy; Molecular Targeted Therapy; Immunotherapy; Overall Survival; Poly(ADP-Ribose) Polymerase Inhibitor